SURAKSHA
Suraksha Diagnostic Limited operates a chain of diagnostic centers in India. It offers pathology testing services, such as microbiology, serology, molecular biology, histopathology, cytopathology, clinical pathology, and haematology; genomics testing, including microarray, noninvasive prenatal, quantitative fluorescent polymerase chain reaction, fluorescence in situ hybridization, and karyotyping… Read more
Market Cap & Net Worth: SURAKSHA (SURAKSHA)
SURAKSHA (NSE:SURAKSHA) has a market capitalization of $28.29K (₹2.45 Million) as of March 18, 2026. Listed on the NSE stock exchange, this India-based company holds position #43312 globally and #2112 in its home market, demonstrating a -1.63% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying SURAKSHA's stock price ₹256.30 by its total outstanding shares 9559 (9.56K).
SURAKSHA Market Cap History: 2025 to 2026
SURAKSHA's market capitalization history from 2025 to 2026. Data shows growth from $29.76K to $28.29K (0.00% CAGR).
SURAKSHA Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how SURAKSHA's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
SURAKSHA's market cap is 0.00 times its annual revenue
0.77x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
0.00x
SURAKSHA's market cap is 0.00 times its annual earnings
726.25x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2025 | $29.76K | $2.52 Billion | $318.24 Million | 0.00x | 0.00x |
Competitor Companies of SURAKSHA by Market Capitalization
Companies near SURAKSHA in the global market cap rankings as of March 18, 2026.
Key companies related to SURAKSHA by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #90 globally with a market cap of $177.20 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #151 globally with a market cap of $122.79 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #466 globally with a market cap of $46.38 Billion USD.
- Lonza Group Ltd (PINK:LZAGF): Ranked #511 globally with a market cap of $41.73 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #90 | Thermo Fisher Scientific Inc | NYSE:TMO | $177.20 Billion | $472.71 |
| #151 | Danaher Corporation | NYSE:DHR | $122.79 Billion | $195.21 |
| #466 | IDEXX Laboratories Inc | NASDAQ:IDXX | $46.38 Billion | $586.98 |
| #511 | Lonza Group Ltd | PINK:LZAGF | $41.73 Billion | $596.13 |
SURAKSHA Historical Marketcap From 2025 to 2026
Between 2025 and today, SURAKSHA's market cap moved from $29.76K to $ 28.29K, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₹28.29K | -4.95% |
| 2025 | ₹29.76K | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of SURAKSHA was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $28.29K USD |
| MoneyControl | $28.29K USD |
| MarketWatch | $28.29K USD |
| marketcap.company | $28.29K USD |
| Reuters | $28.29K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.